Conversely, a different study found that just 21 days of daily supplementation with 200 mg of a NAC prescription drug was sufficient to demonstrate its antioxidant properties in patients at risk for metabolic syndrome (10)
It achieves this by binding directly to GHS-R within the hypothalamus and pituitary gland and mimicking the inhibitory effect of somatostatin, leading to a surge of GH release
Thoracic Surgery Clinics 34(3):207-212, 2024
Indeed, it is known in mammals that not all AhpC-PRX1 genes are equally sensitive to hyperoxidation
Vol.22(23), p.13068
PubMed ID: 10204116 GHRP-2 vs Other GHS-R1a Research Peptides Feature GHRP-2 GHRP-6 Ipamorelin Hexarelin Sequence D-Ala-D-Nal-Ala-Trp-D-Phe-Lys-NH (6aa) His-D-Trp-Ala-Trp-D-Phe-Lys-NH (6aa) Aib-His-D-2-Nal-D-Phe-Lys-NH (5aa) His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH (6aa) GHS-R1a Activity More potent than GHRP-6 Potent (founding reference) Potent (most selective) Most potent classic GHRP CD36 Binding Yes (confirmed) Yes (confirmed) Not established Yes (confirmed) ACTH/Cortisol Release Yes (significant) Yes (significant) No (selective GH only) Yes (significant) GHRH Co-Dependency Partial Yes (82% of GH response) Partial Partial GI Motility Research Limited Yes (motilin receptor interaction) Not established Limited Cardioprotection Research Moderate Extensive None Extensive Wound Healing Research None established Published (PPAR/TGF-) None None CD36 Drug Discovery Secondary scaffold Primary scaffold None Secondary Historical Significance High-potency second-generation GHRP Discovery peptide (led to ghrelin) First selective GHRP Most potent classic GHRP GHRP-2s combination of enhanced GHS-R1a potency relative to GHRP-6, confirmed CD36 pharmacology, significant HPA axis co-stimulation, and role as a second-generation comparative reference compound makes it an essential research tool for GH axis biology, pituitary pharmacology, and cytoprotective pathway research occupying a distinct niche from the selective Ipamorelin (no HPA co-stimulation, no CD36), the more extensively CD36-characterised GHRP-6 (lower GHS-R1a potency), and the extremely potent Hexarelin (more restricted research application)
